Business Wire

Airgain Signs Strategic Memorandum of Understanding With COMPAL, a Global Fortune 500 Leader, on Airgain’s 5G Smart FWA Technology

Share

Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, has signed a strategic Memorandum of Understanding (MOU) with Compal Electronics, Inc. (TAIEX: 2324), a global fortune 500 leader in smart device manufacturing, on a comprehensive plan for commercialization of a 5G Smart Fixed Wireless Access (FWA) technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530558164/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yiyun Chang, Vice President at Compal Electronics, Inc. (left), shaking hands with Dr. Ali Sadri, CTO of Airgain, Inc., after signing a strategic MOU. (Photo: Business Wire)

The agreement signals a major step towards enabling mass production of this transformative technology which has the potential to substantially enhance 5G customer experience and mobile network operator (MNO) capabilities.

Airgain Smart LanternTM uses patent-pending smart beamforming technology to simplify end-user FWA deployment as well as reducing truck roll and professional installation, by automatically determining the direction of the best received and transmitted signal from the 5G cellular base station (gNb).

Preliminary testing results indicate a performance enhancement exceeding 25% in both throughput and range when compared to conventional indoor and outdoor omnidirectional Fixed Wireless Access (FWA) Customer Premises Equipment (CPE).

The MOU commits the two companies to a collaboration which will see them evaluate the technology’s 5G KPI enhancements and assess the feasibility, effectiveness, and opportunities for original equipment manufacturer (OEM) and original device manufacturer (ODM) for FWA device development.

At the heart of the innovation is Airgain’s first-of-its-kind smart antenna technology for 5G mid-band and C-band frequencies, and novel beamforming algorithms. When combined with COMPAL’s expertise in developing FWA modules leveraging leading 5G chipset providers, this will deliver a powerful value proposition to their customers.

According to the forecast presented in the Ericsson Mobility Report, the Fixed Wireless Access (FWA) market is projected to reach a valuation of $67 billion by the year 2028, which equates to a Compound Annual Growth Rate (CAGR) of 16% year-over-year. Smart Lantern's FWA technology holds the potential to significantly drive the adoption of FWA technology among Mobile Network Operators (MNOs).

Dr. Ali Sadri, CTO of Airgain, Inc., heralded the MOU as a significant moment in bringing Smart LanternTM to market, adding:

“As we embark on this ground-breaking journey towards enabling commercialization, the signing of this MOU with COMPAL signifies a strategic leap forward in realizing the full potential of our innovative product, Smart LanternTM.

“Having demonstrated its feasibility and generated tremendous excitement at Mobile World Congress, this MOU underscores our commitment to translating that enthusiasm into tangible market success. This momentous partnership solidifies Airgain's position as a trailblazer in delivering cutting-edge solutions that shape the future landscape of wireless communication.”

Yiyun Chang, Vice President at Compal Electronics, Inc., said:

“COMPAL’s mission is to foster collaborative innovation and make ideas happen. Our collaboration with Airgain is built on shared dedication to pushing the boundaries of what's possible in the telecommunications industry. We are confident that this partnership will not only meet but exceed the expectations of telecom equipment manufacturers (TEMs), MNOs, and system integrators (SI).

“Together, we are poised to redefine the standards and capabilities of wireless communication, reinforcing COMPAL’s commitment to delivering state-of-the-art solutions that shape the future of connectivity.”

For more information about Smart LanternTM visit airgain.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Airgain Media Contact
Martyn Gettings +44 7831 158416
pr@airgain.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 05:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure22.6.2024 00:00:00 EEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 23:58:00 EEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 23:30:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 23:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye